Sarepta Therapeutics,, Inc. Common Stock

SRPTNASDAQ • USD
20.64 USD
↘ 0.04 (0.19%)AT CLOSE (11:59 AM EDT)
20.70
↗ 0.06 (0.29%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
20.70
↗ 0.06 (0.29%)
🔴Market: CLOSED
Open?$21.06
High?$21.10
Low?$20.39
Prev. Close?$20.68
Volume?2.6M
Avg. Volume?3.1M
VWAP?$20.68
Rel. Volume?0.82x
Bid / Ask
Bid?$19.66 × 100
Ask?$21.93 × 100
Spread?$2.27
Midpoint?$20.80
Valuation & Ratios
Market Cap?2.2B
Shares Out?105.0M
Float?96.6M
Float %?92.2%
P/E Ratio?N/A
P/B Ratio?1.90
EPS?-$6.80
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.32Strong
Quick Ratio?1.48Adequate
Cash Ratio?0.73Adequate
Debt/Equity?0.73Moderate
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
N/A▾
P/B?
1.90CHEAP▾
P/S?
0.99CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
-3.6CHEAP▾
EV/Sales?
1.00CHEAP▾
Returns & Efficiency
ROE?
-62.6%WEAK▾
ROA?
-21.3%WEAK▾
Cash Flow & Enterprise
FCF?$-307451000
Enterprise Value?$2.2B
Related Companies
MGTXBMRNMGXNTLADSGNOCGNIRDABEOKRYSSLDBNGNETSHAQUREBNTCRCKTTNYACRSPVRTXFOLDBEAM
News
Profile
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Employees
835
Market Cap
2.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.sarepta.com
Listed
1997-06-04
Address
215 FIRST STREET
CAMBRIDGE, MA 02142
Phone: 617-274-4000
MarketsMoversWatchlist